Background: CD4 + T cells are critical effectors of anti-tumor immunity, but how tumor cells influence CD4 + T cell effector function is not fully understood. Tumor cell-released autophagosomes (TRAPs) are being recognized as critical modulators of host anti-tumor immunity during tumor progression. Here, we explored the mechanistic aspects of TRAPs in the modulation of CD4 + T cells in the tumor microenvironment.
Background

CD4
+ T cells play a critical role in modulating both innate and adaptive anti-tumor immune responses. Research over the past two decades has revealed that CD4 + effector T cells, especially IFN-γ-producing T helper 1 (Th1) cells, can exhibit anti-tumor activity [1] . However, other subtypes of tumor-infiltrating CD4 + T cells may play a pro-tumorigenic role in the tumor microenvironments via the secretion of inflammatory or regulatory cytokines, such as interleukin (IL)-6, IL-10, IL-17, IL-21, and transforming growth factor (TGF)-β, as the abundance of such CD4 + T cells has been associated with a poor clinical outcome of various types of cancer [1] [2] [3] [4] . It has also become clear that many tumor-derived molecules or extracellular vesicles likely influence the differentiation of CD4 + T cells [5, 6] . However, the precise mechanisms underlying CD4 + T cell differentiation and functions in the tumor microenvironment are not completely understood.
Extracellular vesicles (EVs) have emerged as a new mode of intercellular communication by functioning as the carriers of bioactive molecules to influence the extracellular environment and the immune system [6] [7] [8] . Recent evidences indicate that secretory autophagy, in contrast to canonical autophagy, is an alternative non-degradative mechanism for cellular trafficking and unconventional secretion of proteins and small molecules [9] , such as IL-1β [10] , high mobility group box 1 (HMGB1) [11] , adenosine triphosphate (ATP) [12] , TGF-β [13] , and lysozyme [14] . More importantly, secretory autophagosomes carrying cytoplasmic cargoes, including tumor-specific antigens or viruses, fail to fuse with lysosomes and instead are released into the extracellular environment by the cells under stress [15, 16] .
We have previously found extracellular secretory autophagosomes from the supernatant of tumor cells or malignant effusions and ascites of cancer patients [17, 18] , and have termed such tumor-released autophagosomes TRAPs. We confirmed that TRAPs can be taken up by phagocytes such as neutrophils and macrophages, as well as B cells, and endow them with immunosuppressive activities [18] [19] [20] . These observations highlight that TRAPs are part of an elaborate network of tumor-derived vesicles that can reroute the immune response towards a cancerpromoting direction and should be targeted to improve cancer therapy. However, the mechanistic aspects of TRAPs in the modulation of immune cell function, especially the key anti-tumor effector cell, CD4 + T cell, in the tumor microenvironment and during tumor progression are unclear.
Here, we demonstrate that TRAPs could educate CD4 + T cells to produce IL-6 that functions in an autocrine manner to promote the production of IL-10 and IL-21. TRAPs-elicited CD4 + T cells (T TRAP ) directly inhibit the anti-tumor IFN-γ response of CD4 + T and CD8 + T cells and also induce IL-10 + Bregs, which creates a favorable environment to facilitate tumor growth and metastasis. Mechanistic studies revealed that membrane-bound HSP90α on intact TRAPs is crucial for inducing IL-6 production in CD4 + T cells via a TLR2-MyD88-NF-κB signal cascade. Moreover, autocrine IL-6 further stimulates CD4 + T cells to produce IL-10 and IL-21 via STAT3. Our study unveils novel cellular and molecular mechanisms of tumor-derived extracellular vesicles in regulating CD4
+ effector T cell function and pinpoint TRAPs as a therapeutic target for cancer immunotherapy.
Materials and methods
Human subjects
Malignant pleural effusions and ascites were collected from cancer patients pathologically diagnosed with multiple cancer types. The clinicopathological characteristics of the enrolled patients are presented in Additional file 1: Table S1 . The study was approved by the Ethics Committee for Human Studies of Southeast University (protocol 2016ZDKYSB112).
Mice
C57BL/6 female mice were purchased from the Comparative Medicine Center of Yangzhou University.
Tlr4
−/− , Tlr2 −/− , Myd88 −/− and OT-I mice were purchased from the Nanjing Biomedical Research Institute of Nanjing University (Nanjing, China). Il6 −/− mice were gifts from Dr. Jinping Zhang (Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China). Mice were maintained in the barrier facility at Southeast University. All animal experiments were approved by the Institutional Animal Care and Use Committee of Southeast University.
Cell culture
The murine hepatic carcinoma line Hepa1-6, melanoma line B16F10, Lewis lung carcinoma line LLC, lymphoma line EL4, and the human melanoma line A375, hepatic carcinoma line HepG2 and breast carcinoma line MDA-MB-231 were cultured in complete RPMI-1640 medium with 10% FBS (Gibco), 100 U/ml penicillin and 0.1 mg/ml streptomycin at 37°C in a 5% CO 2 incubator. Becn1 knockdown (Becn1 KD) and negative control B16F10 cells (Becn1 NC) were established by using lentivirus expressing Becn1-targeting (5′-GCGGGAGUAUA GUGAGUUUTT-3′) and scrambled (5′-TTCTCCGAA CGTGTCACGTAA-3′) shRNA (Hanbio Biotechnology, Shanghai, China), respectively.
Chemicals
The inhibitors PD98059, SP600125, SB203580, LY294002, BAY11-7082, and Stattic were purchased from MCE (Shanghai, China). Recombinant murine IL-2 and IL-12 were purchased from PeproTech (Rocky Hill, USA). CFSE were purchased from Invitrogen/Thermo Fisher Scientific. IL-6, IL-10 and IL-21 neutralizing antibodies were purchased from R&D Systems. Lymphocyte separation media were purchased from MultiSciences (Hangzhou, China). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO).
TRAPs purification and characterization
Tumor cells were seeded in a T175 flask in complete RPMI-1640 culture medium supplemented with 10% heat-inactivated FBS (Gibco), 100 U/ml penicillin, and 0.1 mg/ml streptomycin and incubated for 3-4 days at 37°C, 5% CO 2 until 100% confluency was reached. Tumor cell culture supernatants were collected for TRAPs isolation as described previously [18, 20] . Briefly, supernatants were centrifuged at 2000 rpm for 10 min to remove whole cells and debris. The supernatants were further centrifuged at 12,000 g for 30 min to harvest the TRAPs-containing pellet. The TRAPs-containing pellet was washed three times with PBS and isolated with magnetic beads (Miltenyi Biotec) combined with LC3b antibody (Cell Signaling Technology) for TRAPs. The purity of TRAPs was analyzed by flow cytometry and western blot. The size of TRAPs was determined by dynamic light scattering using a Malvern Instrument.
Primary cell isolation
Mouse splenic B cells (Invitrogen, 11422D), CD4 + T cells (Invitrogen, 11415D), CD8 + T cells (Invitrogen, 11417D) and human peripheral blood CD4 + T cells (Miltenyi Biotec, 130-045-101) were purified by magnetic-activated cell sorting (MACS) following the manufacturer's instructions. After the MACS, the purity of T and B cells were > 95% as assessed by flow cytometry.
Flow cytometry
Purified CD4
+ T or CD8 + T cells were cultured in a 24-well plate pre-coated with 2 μg/ml anti-CD3 (BD Biosciences, 550,275) and 2 μg/ml anti-CD28 mAb (BD Biosciences, 553,294) in the presence of 50 U/ml IL-2 (PeproTech), purified TRAPs and 30% culture supernatants from CD4 + T cells or B cells. In some cases, culture supernatants from CD4 + T cells or B cells were pretreated with neutralizing mAbs against IL-6, IL-10, or IL-21 for 1 h at 4°C and subsequently exposed to T cells or B cells. Three days later, IFN-γ + CD4 + T, IFN-γ + CD8 + T or IL-10 + B cells were evaluated by flow cytometry. For intracellular staining, the cells were stimulated with the ovalbumin (OVA) protein or anti-CD3 and anti-CD28 mAbs at 37°C for 24 or 72 h. Leukocyte activation cocktail and GolgiPlug (BD Biosciences) were added to the culture 5 h prior to flow cytometric analysis. Subsequently, the cells were stained with antibodies specific to the various surface molecules, fixed and permeabilized with a Fixation/Permeabilization Kit (BD Biosciences), and finally stained with antibodies against the various intracellular molecules. To detect Bcl-6 and Foxp3, the cells were fixed and permeabilized using a Transcription Factor Buffer Set (BD Biosciences). Data were acquired using a FACS Calibur analyzer (BD Biosciences) and analyzed by FlowJo. The gates were set according to the staining by isotype-matched control antibodies of the respective cells. The fluorochrome-conjugated Abs used are listed in Additional file 1: Table S2 .
Quantitative real-time PCR
Total RNA from CD4 + T cells was isolated with TRIzol reagent (Invitrogen) and reverse-transcribed using 5 × PrimeScriptRT Master Mix (Takara), following the manufacturer's instructions. The specific primers used to amplify the genes are listed in Additional file 1: Table  S3 . The PCR was performed in triplicate using Fast Start Universal SYBR Green Master (ROX) (Roche Life Science) in a StepOne Real-Time PCR System (Thermo Fisher Scientific). GAPDH was used as an internal standard.
Elisa
Cytokines in the sera or cell culture supernatants were quantified using ELISA kits according to the manufacturer's protocol. ELISA sets were purchased from eBioscience (IL-6 and IL-10) and R&D Systems (IL-21).
Western blot
The proteins samples were extracted from CD4 + T cells with RIPA lysis buffer. They were separated and transferred as previously described [21] . The membranes were blocked with 5% BSA in TBST for 1 h and separately incubated with the primary antibodies overnight at 4°C. After washing with TBST buffer, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h. The results were visualized by enhanced chemiluminescence according to the manufacturer's protocol. The primary antibodies used are listed in Additional file 1: Table S4 .
Animal models
Wild type C57BL/6 mice or Il6 −/− C57BL/6 mice were subcutaneously inoculated with B16F10, B16F10 Becn1 NC or B16F10 Becn1 KD cells (2 × 10 5 cells/mouse). Tumor growth was measured using a caliper. On day 21, draining lymph nodes (dLN), spleens or tumor tissues were harvested from tumor-free or tumor-bearing mice. 
CD4
+ and CD8 + T cells in the spleens was determined by intracellular cytokine staining after ex vivo stimulation with the OVA protein for 24 h.
T and B cell depletion
C57Bl/6 mice (n = 5/group) were inoculated subcutaneously in the flank with 1 × 10 6 Becn1-NC or Becn1-KD B16F10 cells. On day 9, the tumor-bearing mice were subsequently depleted of either CD4 + T cells, CD8 + T cells or CD20 + B cells by intravenous administration of 250 μg/mouse of anti-mouse CD4 (clone GK1.5, BioXCell) or anti-mouse CD8 (clone 2.43, BioXCell) twice weekly throughout the course of tumor growth, or 250 μg of anti-mouse CD20 (clone SA271G2, BioLegend), respectively. Control mice were treated similarly but with isotype-matched control antibodies. Depletion was confirmed by staining of peripheral blood cells with anti-mouse CD4 (RM4-5, BD Pharmingen), anti-mouse CD8 (clone 53-6.7, BioLegend), or anti-mouse CD19 (clone 6D5, BioLegend).
Statistical analysis
Data were derived from at least 3 independent experiments and analyzed using GraphPad Prism 5.0 software.
Multiple group comparisons were performed by oneway ANOVA and the Tukey-Kramer multiple test. Comparisons between 2 groups were performed using unpaired Student's t-test or Mann-Whitney U test. P < 0.05 was considered significant.
Results
TRAPs induce CD4
+ T cells to produce IL-6, IL-10, and IL-21
To determine whether TRAPs impact CD4 + T cell function, we first isolated TRAPs from the culture supernatants of mouse B16F10 melanoma cells [18, 19] . The TRAPs preparation specifically contained the mature autophagosome marker LC-3II (Fig. 1a, b) and exhibited an average size of 436.3 nm, which was distinct from isolated exosomes that had an average size of 85.6 nm ( Figure S1d ). Depletion of TRAPs from the culture media via ultracentrifugation (Additional file 2: Figure S1e ) resulted in a significant reduction of IL-6, IL-10 and IL-21 production by CD4 + T cells (Fig. 1g) . Intriguingly, we also found that LC3B + EVs (TRAPs) purified from B16F10 culture supernatant were more potent than LC3B − EVs and exosomes in upregulating IL-6 expression, suggesting that LC3B + EVs (TRAPs) are the dominant large EVs that instruct CD4 (Fig. 1h) . Consistently, in B16F10 tumor-bearing mice, the frequency of IL-6 + , IL-21 + and IL-10 + CD4 + T cells in the draining lymph node and spleen were also increased (Fig. 1i) . Taken together, these results show that TRAPs could modulate CD4 + T cell differentiation by inducing IL-6, IL-10, and IL-21 expression and suppressing their IFN-γ production.
TRAPs-induced IL-6, IL-10, and IL-21 production requires TLR2-MyD88 signaling
We then investigated the mechanism by which TRAPs induce IL-6, IL-10, and IL-21 in CD4 + T cells. Within the time frame of the induction of these cytokines, TRAPs adhered to the surface of CD4 + T cells in a dosedependent manner without being internalized (Fig. 2a,  b) , suggesting the involvement of surface molecules on TRAPs that interact with receptors on CD4 + T cells. TRAPs are enriched with various danger-associated molecular patterns (DAMPs) capable of stimulating pattern recognition receptors (PRRs) [17, 18] . CD4 + T cells expressed appreciable levels of TLR2 and TLR4 (Additional file 2: Figure S3a ). We therefore examined whether TLR2 or TLR4 was involved in sensing TRAPs by CD4 + T cells. While TRAPs-induced IL-6, IL-10 and + , IL-10 + or IL-21 + CD4 + T cells in the draining lymph nodes (dLN) and spleens of C57BL/6 tumor-bearing (TB) mice (n = 6) 21 days after s.c. inoculation of B16F10 cells, in comparison to the tumor-free (TF) mice. Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant, by one-way ANOVA with the Tukey-Kramer multiple test, 2-tailed unpaired t-test or MannWhitney U test IL-21 secretion by CD4 + T cells was independent of TLR4, Tlr2 −/− and Myd88 −/− CD4 + T cells were completely defective in producing these cytokines in response to TRAPs (Fig. 2c) . Consistently, TLR2 on the surface of CD4 + T cells was in direct contact with TRAPs (Fig. 2d ). In agreement with the above finding, Tlr2 −/− mice bearing B16F10 tumors had a significant reduction of IL-21 + and IL-10 + CD4 + T cells in the tumor tissue compared to WT tumor-bearing mice (Fig.  2e, f ) . Collectively, these results show that TRAPs induce CD4 + T cells to produce IL-6, IL-10, and IL-21 in a TLR2-and MyD88-dependent manner.
TRAPs-elicited IL-6 production by CD4 + T cells depends on NF-κB/p38/Akt signaling
We further sought to determine the signals downstream of TLR2 in the induction of IL-6, IL-10, and IL-21 by TRAPs. TRAPs treatment of WT CD4 + T cells resulted in the phosphorylation of NF-κB, Akt, p38 and STAT3, but not ERK1/2 or JNK1/2 (Fig. 3a) , whereas TRAPs failed to induce NF-κB, Akt, p38 and STAT3 phosphorylation in Tlr2 −/− or Myd88 −/− CD4 + T cells when compared to CD4 + T cells from WT or Tlr4 −/− mice (Additional file 2: Figure S3b) . Pretreatment of CD4 + T cells with an inhibitor of NF-κB, Akt or p38 attenuated TRAPs-induced secretion of IL-6, IL-10 and IL-21, whereas the inhibition of JNK1/2 or ERK1/2 had no effect (Fig. 3b) . Of note, pretreatment of CD4 + T cells with a STAT3 inhibitor diminished the production of IL-10 and IL-21, but not IL-6, in a dose-dependent manner (Fig. 3b, c) , indicating that NF-κB, Akt, and p38 activation was needed for TRAPs-induced IL-6, IL-10 and IL-21 production but STAT3 activation was only required for IL-10 and IL-21 production.
The induction of IL-10 and IL-21 depends on autocrine IL-6 signaling
The IL-6-STAT3 pathway plays a crucial role in Th cell differentiation [22] . Upon IL-6 neutralization with a blocking antibody, the induction of IL-21 and IL-10 mRNA and proteins by TRAPs was completely abolished, with a concomitant decline of STAT3 phosphorylation ( represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant, by 2-tailed unpaired t-test or Mann-Whitney U test
inguinal lymph node and spleen were much lower in Il6 −/− mice than in WT mice (Fig. 3f, g ). Collectively, these results support a TRAPs-initiated regulatory cascade of CD4 + T cell differentiation involving TLR2-NF-κB/p38/Akt-dependent induction of autocrine IL-6 which then promotes IL-10 and IL-21 expression via STAT3.
Hsp90α is a TRAPs surface ligand that induces IL-6 in CD4 + T cells
To identify the molecular components in TRAPs that are responsible for stimulating CD4 + T cell production of IL-6, we first subjected TRAPs to proteinase K digestion or sonication. These treatments impaired the ability of TRAPs to induce IL-6 from CD4 + T cells (Fig. 4a, b) , times. Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant by one-way ANOVA with the Tukey-Kramer multiple test, 2-tailed unpaired t-test or Mann-Whitney U test
indicating that proteins on the surface, but not the soluble contents, of TRAPs are largely responsible for IL-6 induction in CD4 + T cells. In addition, TRAPs from the hepatic carcinoma Hepa1-6, lung cancer LLC or lymphoma EL4 cells also potently enhanced IL-6 secretion in
CD4
+ T cells (Additional file 2: Figure S5a ). Several ligands of TLR2, including HMGB1, Hsp60, Hsp70, and Hsp90α [18, 23] , were enriched in and present on the surface of TRAPs (Fig. 4c , Additional file 2: Figure S5b) . Blocking of Hsp90α, but not HMGB1, Hsp60 or Hsp70, + T cells treated with TRAPs (3 μg/ml) or blocking antibody-pretreated TRAPs (anti-HMGB1, anti-Hsp60, anti-Hsp70, anti-Hsp90α antibodies) for 72 h in the presence of anti-CD3/CD28. e-g CFSE-labeled TRAPs were pretreated with the indicated dose of functional an anti-Hsp90α antibody or an isotype-matched control antibody overnight at 4°C and then co-cultured with purified CD4 + T cells in the presence of anti-CD3/CD28. Twentyfour hour later, the percentage of CFSE + CD4 + T cells was assessed by flow cytometry (e, f). Seventy-two hour later, IL-6 levels in supernatants were determined by ELISA (g). h The Hsp90α level in tumor cell lysates, an equal amount of TRAPs, sonicated TRAPs, and proteinase K-pretreated TRAPs was determined by western blot. Purified CD4 + T cells were co-cultured with the above stimulators for 72 H. IL-6 levels in the supernatants were determined by ELISA. i ELISA of IL-6 secretion by human CD4 + T cells treated with 3 μg/ml human TRAPs (hTRAPs) from 3 human tumor cell lines (A375, MDA-MB-231 and HepG2 cells) or 8 tumor patient effusions and ascites, respectively for 72 h in the presence of anti-CD3/CD28. j ELISA of IL-6 secretion by human CD4 + T cells treated with hTRAPs (3 μg/ml) or anti-Hsp90α-pretreated hTRAPs for 72 h in the presence of anti-CD3/CD28. Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ns, not significant by one-way ANOVA with the Tukey-Kramer multiple test on the surface of TRAPs partially diminished TRAPsinduced IL-6 secretion by CD4 + T cells, indicating that other molecules on TRAPs may also play a role (Fig. 4d) . Accordingly, an anti-Hsp90α antibody dose-dependently inhibited TRAPs binding to CD4 + T cells (Fig. 4e, f) , reduced TRAPs-induced IL-6 secretion (Fig. 4g) , and suppressed the activation of NF-κB, Akt and p38 (Additional file 2: Figure S5c) . Remarkably, compared to intact TRAPs, tumor cell lysates containing an equal amount of total protein but much more Hsp90α, or sonicated TRAPs containing an equal amount of Hsp90α, or proteinase K-treated TRAPs were much less effective in inducing IL-6 secretion from CD4 + T cells (Fig. 4h) . Taken together, these results show that membrane-bound Hsp90α on intact TRAPs effectively induces IL-6 expression from CD4 + T cells. To further determine whether human TRAPs (hTRAPs) could induce human CD4 + T cells to produce IL-6, we collected hTRAPs from the culture media of 3 human tumor cell lines, A375, MDA-MB-231 and HepG2, and from the malignant effusions or ascites of 8 cancer patients (Additional file 1: Table S1 ). Western blotting analysis revealed that LC3-II was expressed at high levels in the collected hTRAPs and Hsp90α was detected in most of hTRAPs (Additional file 2: Figure S5d ). RT-PCR analysis and ELISA showed that hTRAPs from cancer patients and tumor cell lines efficiently induced human peripheral blood CD4 + T cells to express IL6 transcript and secrete IL-6 (Fig. 4i , Additional file 2: Figure S5e ). Similar to mouse TRAPs, hTRAPs-induced IL-6 transcription and secretion by human CD4 + T were almost completely abolished by pretreatment of hTRAPs with an anti-hsp90α blocking antibody (Fig. 4j , Additional file 2: Figure S5f) . Altogether, these results indicate that induction of CD4 + T cells IL-6 expression by HSP90α on the surface of TRAPs is a common characteristic in humans and mice.
TRAPs-elicited CD4 + T cells (T TRAP ) suppress effector T cells and promote tumorigenesis
To characterize the function of TRAPs-elicited CD4 + T cells (T TRAP ), we activated CD4 + and CD8 + T cells with anti-CD3 and anti-CD28 in culture supernatants harvested from T TRAP or control CD4 + T cells. T TRAP supernatants (SN/T TRAP ) strongly suppressed the secretion of IFN-γ by activated CD4 + and CD8 + T cells (Fig. 5a ). Pretreatment of SN/T TRAP with a neutralizing antibody against IL-6 or IL-10, but not IL-21, abolished its suppressive effect on IFN-γ production by activated CD4 + and CD8 + T cells (Fig. 5b) . We then transferred control CD4 + T cells or T TRAP into C57BL/6 mice that had received OVA-specific Vβ5.1 + CD8 + OT-I T cells and vaccinated with OVA-loaded dendritic cells (DC OVA ). DC OVA vaccination induced the expansion of Vβ5.1 + CD8 + OT-I T cells in the host, which was suppressed by the adoptive transfer of T TRAP but not control CD4 + T cells (Fig. 5c) . Moreover, the transfer of T TRAP but not control CD4 + T cells led to a decrease of IFN-γ + CD8 + and CD4 + T cells induced by DC OVA vaccination (Fig. 5d) . Therefore, T TRAP could suppress T cell IFN-γ response in vivo.
To see whether T TRAP have a tumor-promoting effect in vivo, we subcutaneously (s.c.) inoculated B16F10 melanoma cells into C57BL/6 mice with or without coadministration of control CD4 + T cells or T TRAP . Coadministration of B16F10 cells with T TRAP enhanced tumor growth as compared to inoculation of B16F10 cells alone or co-administration with control CD4 + T cells (Fig. 5e) . When B16F10 melanoma cells were inoculated i.v. together with T TRAP , T TRAP promoted tumor metastasis to the lung (Fig. 5f ) . Collectively, these results show that T TRAP could promote tumor growth and metastasis in vivo.
T TRAP enhance regulatory B cell function via IL-6, IL-10, and IL-21
To better define the immunosuppressive capacity of T TRAP , we examined the impact of T TRAP on regulatory B cell (Breg) differentiation. In accordance with our earlier findings [18] , TRAPs induced B cell differentiation into IL-10-producing Bregs (Fig. 6a) . Moreover, coculture of B cells and CD4 + T cells in the presence of TRAPs led to a marked increase in Bregs differentiation (Fig. 6a) . Consistently, SN/T TRAP could directly promote IL-10 + Bregs differentiation and IL-10 secretion (Additional file 2: Figure S6a, b) . Next, adoptive transfer of T TRAP , but not control CD4 + T cells, also significantly increased the frequency and number of IL-10 + Bregs in vivo (Fig. 6b) . Therefore, TRAPs can promote IL-10 (Fig. 6c) . Neutralizing IL-6, IL-10 or IL-21 partially abolished the effect of SN/T TRAP in promoting IL-10 production of TRAPs-induced B cells (Fig. 6c) . These data indicate that secreted cytokines, including IL-6, IL-10, and IL-21, from T TRAP were involved in promoting (Fig. 6e) . + T cells and injected s.c. into C57BL/6 mice (n = 6 per group). The growth of the tumor was monitored. f B16F10 tumor cells were intravenously injected into C57BL/6 mice (n = 4 to 6 per group) to establish a lung metastasis model. Subsequently, T TRAP or control CD4 + T cells were adoptively transferred i.v. 3 times with 1 d of interval. Three weeks later, the tumor nodules in the lungs were examined. Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant, by 1-way ANOVA with the TukeyKramer multiple test, 2-tailed unpaired t-test or Mann-Whitney U test
Moreover, adoptive transfer of B TRAP + SN/TTRAP decreased the numbers of IFN-γ + CD8 + and CD4 + T cells induced by DC OVA vaccination (Fig. 6f ) and promoted the growth of B16F10 melanoma cells and their metastasis to the lung (Fig. 6g, h ). Taken together, these results suggest that IL-6, IL-10, and IL-21 from T TRAP augment the differentiation and immunosuppressive function of TRAPs-induced B cells to facilitate tumor growth and metastasis.
Inhibition of autophagosomes formation or IL-6 secretion delay tumor growth
Having shown a critical role of TRAPs in the inhibition of anti-tumor immunity, we explored whether inhibition of TRAPs formation by targeting Becn1, a gene essential for autophagosome formation, could abolish the generation of tumor-promoting T TRAP (Additional file 2: Figure S7a, b) . Becn1 knock-down in B16F10 cells diminished intracellular LC3-II accumulation and markedly reduced TRAPs secretion (Additional file 2: Figure  S7b, c) . The culture media collected from Becn1 knockdown B16F10 cells had reduced ability to induce IL-6, IL-10, and IL-21 in CD4 + T cells (Fig. 7a) . In the mice bearing knock-down B16F10 tumors, the frequency of IL-21 + and IL-10 + CD4 + T cells in the tumor draining lymph node and tumor tissue and the serum IL-6 level were significantly reduced as compared to those in the mice bearing control tumors (Fig. 7b-d) . Moreover, the frequency of IL-10 + B cells and IFN-γ + CD4 + T cells in mice bearing Becn1 knock-down tumors was markedly decreased and increased, respectively (Fig. 7e, f ) . Additionally, Becn1 knock-down B16F10 cells exhibited significantly slower growth in vivo (Additional file 2: Figure  S7d ). These results indicate that inhibition of tumor 
CD8
+ T cells in spleens were analyzed by flow cytometry. f C57BL/6 mice were vaccinated with DC OVA and transferred with B TRAP or B TRAP + SN/TTRAP . At day 15, the frequencies of splenic IFN-γ + CD4 + and CD8 + T cells were determined after ex vivo re-stimulation. g, h B16F10 tumor cells were mixed with B TRAP , B TRAP + SN/CD4+ T , or B TRAP + SN/TTRAP and injected s.c. into C57BL/6 mice (n = 4 per group). The growth of tumor was monitored (g). B16F10 tumor cells were injected i.v. into C57BL/6 mice (n = 4 per group) to establish a lung metastasis model. Subsequently, the above-prepared B cells were i.v. transferred every other day for 3 times. Three weeks later, tumor nodules in the lungs were examined (h). Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01, ***, P < 0.001; ns, not significant 
autophagosome formation and release could enhance anti-tumor immunity and inhibit tumor growth in vivo. Furthermore, the growth of both the negative control and Becn1 knock-down B16F10 tumors was inhibited in mice depleted of B cells or CD4 + T cells (Fig. 7g , Additional file 2: Figure S8 ). Depletion of CD8 + T cells resulted in accelerated growth of Becn1 knock-down but not negative control tumors (Fig. 7g , Additional file 2: Figure S8) . Besides, the frequency of IFN-γ-producing CD4 + T cells and CD8 + T cells in Becn1 knock-down tumor tissue was markedly increased (Fig. 7h, i) . Notably, B-cell or CD4 + Tcell depletion resulted in a significant increase of the percentage of intra-tumoral IFN-γ + CD4 + or CD8 + T cells (Fig. 7h, i) . The frequency of tumor-infiltrating B cells was markedly reduced upon CD4 + T cell depletion (Fig. 7j) . These results suggest that the effector function of CD8 + T cells in the tumors was dampened by CD4 + T cells or B cells. In conclusion, TRAPs-educated CD4 + T cells play an important role in promoting tumor growth by inhibiting effector T cell function.
To determine the role of CD4 + T cell-derived IL-6 in the differentiation of IL-10-and IL-21-producing CD4 (Fig. 7k, l) and IL-10 + B cells (Fig. 7m ) in tumor-draining lymph nodes and tumor tissues from Il6 −/− tumor-bearing mice were significantly decreased. Accordingly, B16F10 tumors grew more slowly in Il6 −/− mice than in WT mice (Fig. 7n) . We then inoculated mice with B16F10 cells together with either WT T TRAP or Il6 −/− T TRAP . Mice co-inoculated with B16F10 cells and WT T TRAP showed accelerated growth and lung metastasis as compared to those inoculated with B16F10 cells alone (Fig. 7o-q) . In contrast, co-inoculation of B16F10 cells with Il6 −/− T TRAP resulted in no enhancement of tumor growth and lung metastasis, and the mice even exhibited slightly, albeit not statistically significant, retarded tumor growth (Fig. 7o-q) . These results corroborate the conclusion that T TRAP rely on IL-6 to dampen T cell-mediated antitumor immunity and foster tumor progression, and suggest that targeting TRAPs or IL-6 may be an effective therapeutic strategy for improving cancer immunotherapy.
Discussion
In addition to soluble factors, tumor cell-derived extracellular vesicles are being recognized as critical modulators of host anti-tumor immunity during tumor progression [7, 8, 18, 19, 24] . Among them are autophagosomes generated by secretory autophagy. In contrast to canonical autophagy that functions in a primarily degradative capacity to sustain cellular metabolism and homeostasis and is often induced conditions of cellular stress, such as nutrient starvation, organelle damage, and pathogen infection, secretory autophagy is a nondegradative mechanism for cellular trafficking and unconventional protein secretion [10, 11, 13, 14, 25] . Secretory autophagosomes fail to fuse with lysosomes, but are released into the extracellular environment through fusing with the plasma membrane or other pathways [15, 26] . Abundant autophagosomes have been detected in gastrointestinal tumors and invasive melanomas and have been associated with tumor cell proliferation, metastasis, and poor prognosis [27, 28] . Our previous studies showed that extracellular autophagosomes harvested from the supernatant of tumor cells or malignant effusions and ascites of cancer patients, which we have termed as TRAPs, could promote the generation of IL-10 + Bregs, reactive oxygen species (ROS)-producing neutrophils, and PD-L1 hi macrophages exerting immunoinhibitory activities [18] [19] [20] . other day for 3 times. Three weeks later, tumor nodules in the lungs were examined. r A proposed model for the mechanisms and immunosuppressive functions of TRAPs-induced CD4 + T cells. Data (mean ± SEM) represent 3 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant, by 1-way ANOVA with the Tukey-Kramer multiple test, 2-tailed unpaired t-test or MannWhitney U test
CD4
+ T cells that infiltrate advanced solid tumors consist of different effector cells, such as Th1, Th2, Th17, Tfh or regulatory T cells (Tregs), with distinct impact on antitumor immunity, immune escape, angiogenesis and metastasis [2, 4, 29] , but the influence of the tumors on CD4 + effector T cell differentiation remains incompletely understood. Here, we have revealed a TRAPs-mediated regulatory mechanism of CD4 + T cells differentiation whereby HSP90α on the surface of TRAPs educate CD4 + T cells via a TLR2-autocrine IL-6 cascade to express IL-10 and IL-21 and engender immune suppression to promote tumor growth and metastasis (Fig. 7r) . Our findings have revealed TRAPs as one of the tumor-derived extracellular vesicles that could inhibit anti-tumor immune response by enhancing the generation of immunosuppressive cells.
TLRs play crucial roles in the innate host defense as well as the control of adaptive immunity [30, 31] . Our findings indicated TLR2 as a key receptor for TRAPsmediated IL-6 expression by CD4 + T cells. Exogenous pathogen-associated molecular patterns (PAMPs) and endogenous DAMPs can be recognized by TLRs to trigger the production of various inflammatory mediators [30] . The current findings showed that TRAPs-mediated regulation of CD4 + T cell differentiation involved membrane-associated Hsp90α. Evidences suggested that extracellular Hsp90α could be released to the extracellular space via unconventional secretion, such as exosomes and necrosis [32] . We observed Hsp90α on the surface of TRAPs, indicating that secretory autophagosomes may also be involved in the release of Hsp90α. Moreover, extracellular Hsp90α was reported to function as a DAMP and provoke biological effects through cell surface receptors, including TLRs and CD91 [23, 33] . Early work showed that heat shock proteins gp96, Hsp90, Hsp70, and calreticulin could function as potential adjuvants to stimulate DC antigen cross-presentation and maturation through the CD91 receptor [33] , but Hsp90α was more recently found to also stimulate tumor proliferation and metastasis through binding to cancer cell surface CD91 and be positively correlated with tumor malignancy in cancer patients [34] [35] [36] . The present study uncovers a new role of Hsp90α on the surface of TRAPs as a cancer-associated pathological factor that interferes with host anti-tumor immunity.
Chronic inflammation and increased levels of inflammatory mediators at the tumor site can reroute the immunomodulatory response towards a cancer-promoting direction [4, 37, 38] . IL-6 has a profound effect on CD4 + T cells survival and proliferation [39] . Otherwise, studies also showed that IL-6 has inhibitory effects via the induction of IL-10-producing T and B cells [40, 41] . Moreover, IL-6 also dampens Th1 differentiation and inhibits CD8 + T cell activation and cytokine production [42, 43] . Consistent with the above results, we provided evidences that TRAPs stimulated IL-10 and IL-21 production in CD4 + T cells via an autocrine IL-6 loop. Moreover, IL-6 from T TRAP remarkably suppressed T cell anti-tumor effector function. IL-21 has been identified to be derived mainly from Tfh cells, which was thought to regulate the proliferation, class switching, and plasmacytoid differentiation of B cells and promote the generation and proliferation of human antigen-specific cytotoxic T-cell responses [4, 44, 45] . Mounting evidences have shown that IL-21 also has anti-inflammatory activities by inhibiting DC maturation and stimulating IL-10 production in T and B cells [46] [47] [48] . Nonetheless, the role of CD4 + T cells in Bregs differentiation in the tumor microenvironment has not been addressed. In our investigation, the IL-21 + T TRAP displayed Tfh-associated molecules CXCR5 and Bcl-6. Interestingly, IL-6, IL-10, and IL-21 secretion by T TRAP synergistically enhanced TRAPselicited Breg differentiation and immunosuppressive function. These findings together imply that T TRAP -derived IL-21 is a pleiotropic effector that can either facilitate or thwart tumor growth depending on the cytokine milieu in the tumor microenvironment, warranting careful consideration of the selective targeting of IL-6 or IL-21 for the treatment of cancer in the future.
Many recent studies have suggested that inhibiting tumor autophagy may have anti-tumor effects by modulating the tumor microenvironment [49] [50] [51] . Consistent with this notion, we found that inhibiting autophagy by targeting the key autophagy gene Becn1, which led to a substantial decrease in extracellular TRAPs, could inhibit tumor growth in mice. Of note, inhibiting autophagy resulted in a significant decrease in the frequency of IL-10 + B cells, IL-21 + and IL-10 + CD4 + T cells, as well as a significant increase in IFN-γ + CD4 + T cells, in the tumor-draining lymph nodes and tumor tissue. Thus, intervening tumor release of TRAPs could be an effective strategy for cancer therapy.
Conclusions
In this study, we have revealed that TRAPs can educate CD4 + T cells to promote tumor growth and metastasis through an HSP90α-TLR2-IL-6-IL-10/IL-21 axis and the induction of IL-10 + Bregs. Our study reveals a novel cellular and molecular mechanism of how tumor-derived extracellular vesicles regulate CD4 + effector T cell function and highlights TRAPs and their membrane-bound DAMPs as important therapeutic targets to reverse the immunosuppressive tumor microenvironment.
Additional files
Additional file 1: Table S1 . Clinical and demographic characteristics of the patients presenting with malignant pleural effusions or ascites. Table S2 . Antibodies used in flow cytometry. Table S3 . Primer sequences for qPCR used in our study. Table S4 
